One-fifth of Zantac 75 U.S. sales came "at the expense" of Rx Zantac, Glaxo tells analysts.
This article was originally published in The Tan Sheet
Executive Summary
ONE-FIFTH OF ZANTAC 75 SALES CAME "AT THE EXPENSE" OF Rx ZANTAC, Glaxo Wellcome CEO Richard Sykes told securities analysts in New York City on Aug. 1. Commenting on the "success of Zantac 75," Sykes noted that the H2 antagonist is "rapidly going past Tagamet HB [and] approaching now the level of Pepcid AC." However, Sykes noted, "some of that growth has come at the expense of prescription Zantac sales."